Clinical Trials Logo

Filter by:
NCT ID: NCT02009553 Recruiting - Anxiety Clinical Trials

Pre-procedural Information Sheet Reduces Anxiety of Patients Before Urodynamic Studies

Start date: December 2013
Phase: N/A
Study type: Observational

Urodynamic study may lead to significant anxiety. Our hypothesis is that Urodynamic study is that pre-procedural explanation note about the test may reduce the anxiety level of the patients.

NCT ID: NCT02009475 Completed - Heart Failure Clinical Trials

The Effect of Two Exercise Training Protocols on Physiological and Biochemical Parameters in Congestive Heart Failure

Start date: February 2014
Phase: N/A
Study type: Interventional

The aim of the present study is to evaluate differential lactate removal kinetics in heart failure patients that are trained according to 2 different exercise protocols: (A) High intensity intervals training (HIT); (B) Continuous moderate aerobic training (MAT)

NCT ID: NCT02009150 Active, not recruiting - Breast Cancer Clinical Trials

Evaluation of a Novel Infra-red Breast Imaging System for Risk Assessment in Women at High Risk for Breast Cancer.

Start date: April 2014
Phase:
Study type: Observational

Three-dimensional functional Metabolic Imaging (3D MIRA) is a new infrared imaging technology using the Real Imager 4(RI4) developed by Real Imaging. This technology generates 3D metabolic maps and based on sophisticated machine learning technology, provides objective risk assessment for the presence of malignant tumor. The procedure is non-invasive, comfortable and does not involve ionizing radiation. Moreover, Real Imaging's 3D Functional MIRA is unaffected by breast density and is therefore ideal for evaluating patients with mammographically dense breasts. The purpose of this clinical study is to assess the ability of this novel technology to detect clinically occult breast cancer in a cohort of women that are at high risk for breast cancer. We hypothesize that the combination of screening mammography and metabolic screening (3D MIRA) will result in significantly higher breast cancer detection rates.

NCT ID: NCT02007317 Completed - BCC Clinical Trials

Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study

Start date: November 2013
Phase: Phase 2
Study type: Interventional

This study is single-arm, none randomized, open label, two-dose-cohorts, single center clinical trial for evaluation of the safety and efficacy of Oshadi D and Oshadi R in patients with BCC. Patients will receive Oshadi D and Oshadi R for 60 -90 days until the planned surgical excision of the lesion.

NCT ID: NCT02006654 Completed - Alzheimer's Disease Clinical Trials

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor

STARBRIGHT
Start date: March 2014
Phase: Phase 3
Study type: Interventional

To establish efficacy of idalopirdine as adjunctive therapy to acetylcholinesterase inhibitors (AChEIs) for symptomatic treatment of patients with mild-moderate Alzheimer's disease (AD).

NCT ID: NCT02006641 Completed - Alzheimer's Disease Clinical Trials

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

STARBEAM
Start date: February 2014
Phase: Phase 3
Study type: Interventional

To establish efficacy of Idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).

NCT ID: NCT02006329 Not yet recruiting - NAFLD Clinical Trials

Treatment of Non Alcoholic Fatty Liver Disease With Lifestyle Modification and Acupuncture

Start date: January 2014
Phase: N/A
Study type: Interventional

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver dysfunction worldwide. NAFLD may progress to nonalcoholic steatohepatitis (NASH) and in turn to cirrhosis. To date, the detailed pathogenic mechanism of NAFLD including steatosis and NASH is not fully characterized, although it is regarded as a hepatic manifestation of the metabolic syndrome, sometimes it occurs in the absence of a metabolic syndrome. Based on conventional models of "two-hit" and "multi- hit" hypothesis of NAFLD, the dysregulated lipid metabolism and insulin resistance are considered as the "first hit" of the liver and the following "second hit" or "multi-hit" likely involves oxidative stress, lipid peroxidation, increased inflammatory responses, induced hepatic fibrosis and apoptosis. This emphasizes the multi-factorial pathogenesis of NAFLD and the necessity to treat NAFLD with diabetes-like and multimodal strategy. Several changes in dietary intake have occurred in the past few years, including increased energy intake (24%), and increases in added sugars, flour and cereal products, fruit, added fats and total fat intake. The increasing prevalence of NAFLD is probably directly affected by the contemporary epidemics of obesity, unhealthy dietary pattern, and sedentary lifestyle. Currently, there are two major categories of NAFLD therapy: lifestyle interventions and pharmaceutical therapies, lifestyle interventions in terms of diet and physical activity are regarded as safe and effective, while pharmaceutical interventions showed limited efficacy with unknown safety in the long term ,therefore, the first line of treatment is lifestyle modification. Although lifestyle intervention dose positively affects NAFLD, it has limitations. Patients adherence to dietary intervention is 50%, while those who do adhere, find it difficult to maintain after 12 months. ). Mediterranean diet has been shown to be effective in reducing NAFLD, liver steatosis and improve insulin sensitivity. Acupuncture has been found as an effective treatment for improving quality of life in various medical conditions , including hepatitis . Acupuncture combined with life style intervention has been found effective in the treatment of obesity, metabolic syndrome in terms of weight, lipid regulation, glucose levels and various markers of inflammation. Acupuncture's effect on NAFLD has yet to be studied. We suggest that acupuncture combined with life style intervention can be an effective treatment for NAFLD.

NCT ID: NCT02006069 Terminated - Heart Failure Clinical Trials

MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing

MORE CRT MPP
Start date: December 2013
Phase: N/A
Study type: Interventional

The purpose of this Clinical investigation is to assess the impact of the Multi Point Pacing (MPP) feature at 12 months in the treatment of patients not responding to standard Cardiac Resynchronization Therapy (CRT) after 6 months.

NCT ID: NCT02005848 Completed - Clinical trials for New Onset Type-1 Diabetes

Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes

Start date: April 2014
Phase: Phase 2
Study type: Interventional

A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Study Evaluating the Efficacy and Safety of Human, Alpha-1 Antitrypsin (AAT) [Glassia®] in the Treatment of New Onset Type-1 Diabetes. The study objectives are: - To assess the efficacy of intravenous AAT in treatment of new onset Type 1 Diabetes - To assess the safety and tolerability of intravenous AAT in new onset Type 1 Diabetes pediatric and young adult population.

NCT ID: NCT02003872 Terminated - Obesity Clinical Trials

The Long Term Effect of Adjustable Spaatz 3 Intragastric Balloon on Weight Loss

Start date: January 2015
Phase: N/A
Study type: Interventional

This is an open-label trial investigating the effect of Spatz 3 intragastric balloon on weight loss on obesity and associated co- morbidities. The study aim is to evaluate the effect of the intra gastric balloon on weight reduction and on related co- morbidities during 1 year of balloon implantation and a year following explantation.